Gilead Sciences Analyst Price Targets

Gilead Sciences Inc

GILDNASDAQ

Trade with Public

$156.19

-1.18-0.75%

Ult. Agg.: Oct 16, 6:55 PM

$156.84

-0.53-0.34%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

Utili: I risultati di Q3 2026 tra 12 giorni da adesso in gio ott 29th, dopo la chiusura del mercato

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 9 Quarters

Analyst Consensus — 23 Analysts

19Buy

4Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$138Upside to Avg. PT-11.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$123→$126
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$150→$158
Oct 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$160→$170
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$165→$163
Sep 10, 2026	HSBC	Morten Herholdt	PT Raise	Buy	$155→$175
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$120→$123
Aug 5, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Aug 5, 2026	Needham	Joseph Stringer	Maintained	Buy	$170
Jul 29, 2026	Barclays	Emily Field	PT Cut	Equal-Weight	$155→$145
Jul 27, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$166→$165
Jul 21, 2026	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$146→$127
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$168→$166
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$122→$120
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$157→$156
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Jul 6, 2026	HSBC	Morten Herholdt	Upgrade	Hold→Buy	$133→$155
Jun 16, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
May 20, 2026	Maxim Group	Michael Okunewitch	Upgrade	Hold→Buy	$165
May 8, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$155→$157

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.

Benzinga Newsdesk

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.

Benzinga Newsdesk

Gilead Sciences Inc

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

People Also Watch

People Also Watch

Gilead Sciences Inc

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PROCantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PROHSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PROCantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PROHSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175